Diagnosis and treatment of hepatocellular carcinoma;Diagnóstico y tratamiento del carcinoma hepatocelular

Medicina Clinica

Volumn 132, Issue 7, 2009, Pages 272-287

  Forner, Alejandro ^a   Ayuso, Carmen ^a   Isabel Real, María ^a   Sastre, Javier ^b   Robles, Ricardo ^c   Sangro, Bruno ^d   Varela, María ^e   de la Mata, Manuel ^f   Buti, María ^g   Martí Bonmatí, Luís ^h   Bru, Concepció ^a   Tabernero, Josep ^g   Llovet, Josep M ^a,i   Bruix, Jordi ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e UNIVERSITY OF OVIEDO   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL UNIVERSITARIO DR PESET   (Spain)

ⁱ Division of Liver Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; BRIVANIB; CETUXIMAB; ERLOTINIB; EVEROLIMUS; NOLATREXED; SEOCALCITOL; SORAFENIB; SUNITINIB; TAMOXIFEN;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PROGNOSIS; RADIOFREQUENCY ABLATION; SPAIN;

ALGORITHMS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PROGNOSIS; PYRIDINES;

EID: 60849128182     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2008.11.024     Document Type: Article

References (208)

1. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
3. Bosch F.X., Ribes J., Diaz M., and Cleries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127 5 Suppl 1 (2004) S5-S16
4. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336 26 (1997) 1855-1859
5. Khan S.A., Taylor-Robinson S.D., Toledano M.B., Beck A., Elliott P., and Thomas H.C. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37 6 (2002) 806-813
6. elSaadany S., Tepper M., Mao Y., Semenciw R., and Giulivi A. An epidemiologic study of hepatocellular carcinoma in Canada. Can J Public Health 93 6 (2002) 443-446
7. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 10 (1999) 745-750
8. Kiyosawa K., Umemura T., Ichijo T., Matsumoto A., Yoshizawa K., Gad A., et al. Hepatocellular carcinoma: Recent trends in Japan. Gastroenterology 127 5 Suppl 1 (2004) S17-S26
9. Fattovich G., Stroffolini T., Zagni I., and Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 127 5 Suppl 1 (2004) S35-S50
10. Morgan T.R., Mandayam S., and Jamal M.M. Alcohol and hepatocellular carcinoma. Gastroenterology 127 5 Suppl 1 (2004) S87-S96
11. La Vecchia C., Lucchini F., Franceschi S., Negri E., and Levi F. Trends in mortality from primary liver cancer in Europe. Eur J Cancer 36 7 (2000) 909-915
12. Ribes J., Cleries R., Borras J., Galceran J., and Bosch F.X. Time trends in incidence and mortality for chronic liver disease and liver cancer in the interval 1980-1997 in Catalonia, Spain. Eur J Gastroenterol Hepatol 16 9 (2004) 865-872
13. Bruno S., Stroffolini T., Colombo M., Bollani S., Benvegnu L., Mazzella G., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 45 3 (2007) 579-587
14. Adami H.O., Chow W.H., Nyren O., Berne C., Linet M.S., Ekbom A., et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 88 20 (1996) 1472-1477
15. Regimbeau J.M., Colombat M., Mognol P., Durand F., Abdalla E., Degott C., et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 10 2 Suppl 1 (2004) S69-S73
16. Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J.W., and Powell L.W. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 11 1 (1990) 74-80
17. Ratziu V., Bonyhay L., Di Martino V., Charlotte F., Cavallaro L., Sayegh-Tainturier M.H., et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35 6 (2002) 1485-1493
18. Calle E.E., Rodriguez C., Walker-Thurmond K., and Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348 17 (2003) 1625-1638
19. Kuper H., Tzonou A., Kaklamani E., Hsieh C.C., Lagiou P., Adami H.O., et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 85 4 (2000) 498-502
20. Marrero J.A., Fontana R.J., Fu S., Conjeevaram H.S., Su G.L., and Lok A.S. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 42 2 (2005) 218-224
21. Bravi F., Bosetti C., Tavani A., Bagnardi V., Gallus S., Negri E., et al. Coffee drinking and hepatocellular carcinoma risk: A meta-analysis. Hepatology 46 2 (2007) 430-435
22. Gelatti U., Covolo L., Franceschini M., Pirali F., Tagger A., Ribero M.L., et al. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: A case-control study. J Hepatol 42 4 (2005) 528-534
23. Tanaka K., Hara M., Sakamoto T., Higaki Y., Mizuta T., Eguchi Y., et al. Inverse association between coffee drinking and the risk of hepatocellular carcinoma: A case-control study in Japan. Cancer Sci 98 2 (2007) 214-218
24. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 15 (2004) 1521-1531
25. Heathcote E.J. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 127 5 Suppl 1 (2004) S294-S302
26. Yang H.I., Lu S.N., Liaw Y.F., You S.L., Sun C.A., Wang L.Y., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347 3 (2002) 168-174
27. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 295 1 (2006) 65-73
28. Sangiovanni A., Prati G.M., Fasani P., Ronchi G., Romeo R., Manini M., et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 43 6 (2006) 1303-1310
29. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 9399 (2003) 1907-1917
30. Zhang B.H., Yang B.H., and Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130 7 (2004) 417-422
31. Zhang B., and Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 6 2 (1999) 108-110
32. Wong L.L., Limm W.M., Severino R., and Wong L.M. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 6 3 (2000) 320-325
33. Bolondi L., Sofia S., Siringo S., Gaiani S., Casali A., Zironi G., et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost effectiveness analysis. Gut 48 2 (2001) 251-259
34. Sangiovanni A., Del Ninno E., Fasani P., De Fazio C., Ronchi G., Romeo R., et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126 4 (2004) 1005-1014
35. Sarasin F.P., Giostra E., and Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 101 4 (1996) 422-434
36. Arguedas M.R., Chen V.K., Eloubeidi M.A., and Fallon M.B. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: A cost-utility analysis. Am J Gastroenterol 98 3 (2003) 679-690
37. Lin O.S., Keeffe E.B., Sanders G.D., and Owens D.K. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 19 11 (2004) 1159-1172
38. Barbara L., Benzi G., Gaiani S., Fusconi F., Zironi G., Siringo S., et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 16 1 (1992) 132-137
39. Ebara M., Hatano R., Fukuda H., Yoshikawa M., Sugiura N., and Saisho H. Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients. Hepatogastroenterology 45 Suppl 3 (1998) 1214-1220
40. Trinchet J. Screening for hepatocellular carcinoma (HCC) in patients with cirrhosis. A multicenter randomized trial comparing two periodicities of ultrasonographic (US) screening, 3 months vs 6 months. J Hepatol 46 Suppl 1 (2007) S56
41. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 39 6 (2003) 1076-1084
42. Brenner D.J., and Hall E.J. Computed tomography--an increasing source of radiation exposure. N Engl J Med 357 22 (2007) 2277-2284
43. Trevisani F., D'Intino P.E., Morselli-Labate A.M., Mazzella G., Accogli E., Caraceni P., et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status. J Hepatol 34 4 (2001) 570-575
44. Forner A., Vilana R., Ayuso C., Bianchi L., Sole M., Ayuso J.R., et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47 1 (2008) 97-104
45. Kemmer N., Neff G., Kaiser T., Zacharias V., Thomas M., Tevar A., et al. An analysis of the UNOS liver transplant registry: High serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma. Liver Transpl 12 (2006) 1519-1522
46. Sherman M. Alphafetoprotein: An obituary. J Hepatol 34 4 (2001) 603-605
47. Shiraki K., Takase K., Tameda Y., Hamada M., Kosaka Y., and Nakano T. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 22 3 (1995) 802-807
48. Marrero J.A., Su G.L., Wei W., Emick D., Conjeevaram H.S., Fontana R.J., et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 37 5 (2003) 1114-1121
49. Capurro M., Wanless I.R., Sherman M., Deboer G., Shi W., Miyoshi E., et al. Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125 1 (2003) 89-97
50. Kojiro M., and Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 25 2 (2005) 133-142
51. Burrel M., Llovet J.M., Ayuso C., Iglesias C., Sala M., Miquel R., et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation. Hepatology 38 4 (2003) 1034-1042
52. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 3 (2001) 421-430
53. Bolondi L., Gaiani S., Celli N., Golfieri R., Grigioni W.F., Leoni S., et al. Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma. Hepatology 42 1 (2005) 27-34
54. Marrero J.A., Hussain H.K., Nghiem H.V., Umar R., Fontana R.J., and Lok A.S. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 11 3 (2005) 281-289
55. Kim S.J., Lee J.M., Han J.K., Kim K.H., Lee J.Y., and Choi B.I. Peripheral mass-forming cholangiocarcinoma in cirrhotic liver. AJR Am J Roentgenol 189 6 (2007) 1428-1434
56. Bru C., Maroto A., Bruix J., Faus R., Bianchi L., Calvet X., et al. Diagnostic accuracy of fine-needle aspiration biopsy in patients with hepatocellular carcinoma. Dig Dis Sci 34 11 (1989) 1765-1769
57. Caturelli E., Biasini E., Bartolucci F., Facciorusso D., Decembrino F., Attino V., et al. Diagnosis of hepatocellular carcinoma complicating liver cirrhosis: Utility of repeat ultrasound-guided biopsy after unsuccessful first sampling. Cardiovasc Intervent Radiol 25 4 (2002) 295-299
58. Stigliano R., Marelli L., Yu D., Davies N., Patch D., and Burroughs A.K. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 33 5 (2007) 437-447
59. Farinati F., Marino D., De Giorgio M., Baldan A., Cantarini M., Cursaro C., et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: Both or neither?. Am J Gastroenterol 101 3 (2006) 524-532
60. Mueller S.B., Micke O., Herbst H., Schaefer U., and Willich N. Alpha-fetoprotein-positive carcinoma of the pancreas: A case report. Anticancer Res 25 3A (2005) 1671-1674
61. Ishikawa K., Sasaki A., Haraguchi N., Yoshikawa Y., and Mori M. A case of an alpha-fetoprotein-producing intrahepatic cholangiocarcinoma suggests probable cancer stem cell origin. Oncologist 12 3 (2007) 320-324
62. Thorgeirsson S.S., and Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31 4 (2002) 339-346
63. Villanueva A., Newell P., Chiang D.Y., Friedman S.L., and Llovet J.M. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27 1 (2007) 55-76
64. Llovet J.M., Chen Y., Wurmbach E., Roayaie S., Fiel M.I., Schwartz M., et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 131 6 (2006) 1758-1767
65. Paradis V., Bieche I., Dargere D., Laurendeau I., Laurent C., Bioulac Sage P., et al. Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: Determination of a molecular diagnostic index. Am J Pathol 163 2 (2003) 733-741
66. Di Tommaso L., Franchi G., Park Y.N., Fiamengo B., Destro A., Morenghi E., et al. Diagnostic value of HSP70, Glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 45 3 (2007) 725-734
67. Greene F., Page D., Fleming I., Fritz A., Balck C., Haller D., et al. Cancer staging handbook (2002), Springer Verlag, New York
68. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., and Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 8 (1973) 646-649
69. Kamath P.S., Wiesner R.H., Malinchoc M., Kremers W., Therneau T.M., Kosberg C.L., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33 2 (2001) 464-470
70. Sorensen J.B., Klee M., Palshof T., and Hansen H.H. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 67 4 (1993) 773-775
71. Verger E., Salamero M., and Conill C. Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa?. Eur J Cancer 28A 8-9 (1992) 1328-1330
72. Okuda K., Ohtsuki T., Obata H., Tomimatsu M., Okazaki N., Hasegawa H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56 4 (1985) 918-928
73. Stuart K.E., Anand A.J., and Jenkins R.L. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 77 11 (1996) 2217-2222
74. Llovet J.M., Bru C., and Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 19 3 (1999) 329-338
75. Llovet J.M., Bustamante J., Castells A., Vilana R., Ayuso Mdel C., Sala M., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 29 1 (1999) 62-67
76. Chevret S., Trinchet J.C., Mathieu D., Rached A.A., Beaugrand M., and Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol 31 1 (1999) 133-141
77. Caselitz M., Masche N., Flemming P., Stern C., Manns M.P., Wagner S., et al. Prognosis of hepatocellular carcinoma according to new staging classification. Dtsch Med Wochenschr 129 33 (2004) 1725-1730
78. Schoniger-Hekele M., Muller C., Kutilek M., Oesterreicher C., Ferenci P., and Gangl A. Hepatocellular carcinoma in Central Europe: Prognostic features and survival. Gut 48 1 (2001) 103-109
79. Leung T.W., Tang A.M., Zee B., Lau W.Y., Lai P.B., Leung K.L., et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients. Cancer 94 6 (2002) 1760-1769
80. Omagari K., Honda S., Kadokawa Y., Isomoto H., Takeshima F., Hayashida K., et al. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. J Gastroenterol Hepatol 19 7 (2004) 805-811
81. Villa E., Moles A., Ferretti I., Buttafoco P., Grottola A., Del Buono M., et al. Natural history of inoperable hepatocellular carcinoma: Estrogen receptors status in the tumor is the strongest prognostic factor for survival. Hepatology 32 2 (2000) 233-238
82. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28 3 (1998) 751-755
83. Kudo M., Chung H., Haji S., Osaki Y., Oka H., Seki T., et al. Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score. Hepatology 40 6 (2004) 1396-1405
84. Tateishi R., Yoshida H., Shiina S., Imamura H., Hasegawa K., Teratani T., et al. Proposal of a new prognostic model for hepatocellular carcinoma:A analysis of 403 patients. Gut 54 3 (2005) 419-425
85. Sala M., Forner A., Varela M., and Bruix J. Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis 25 2 (2005) 171-180
86. Cillo U., Bassanello M., Vitale A., Grigoletto F.A., Burra P., Fagiuoli S., et al. The critical issue of hepatocellular carcinoma prognostic classification: Which is the best tool available?. J Hepatol 40 1 (2004) 124-131
87. Grieco A., Pompili M., Caminiti G., Miele L., Covino M., Alfei B., et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: Comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54 3 (2005) 411-418
88. Marrero J.A., Fontana R.J., Barrat A., Askari F., Conjeevaram H.S., Su G.L., et al. Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort. Hepatology 41 4 (2005) 707-716
89. Llovet J.M., Di Bisceglie A.M., Bruix J., Kramer B.S., Lencioni R., Zhu A.X., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100 10 (2008) 698-711
90. Lee J.S., Chu I.S., Heo J., Calvisi D.F., Sun Z., Roskams T., et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40 3 (2004) 667-676
91. Boyault S., Rickman D.S., de Reynies A., Balabaud C., Rebouissou S., Jeannot E., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45 1 (2007) 42-52
92. Chiang D.Y., Villanueva A., Hoshida Y., Peix J., Newell P., Minguez B., et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68 16 (2008) 6779-6788
93. Llovet J., and Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48 Suppl 1 (2008) S20-S37
94. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359 19 (2008) 1995-2004
95. Bismuth H., and Majno P.E. Hepatobiliary surgery. J Hepatol 32 1 Suppl (2000) 208-224
96. Belghiti J., Hiramatsu K., Benoist S., Massault P., Sauvanet A., and Farges O. Seven hundred forty-seven hepatectomies in the 1990s: An update to evaluate the actual risk of liver resection. J Am Coll Surg 191 1 (2000) 38-46
97. Llovet J.M., Schwartz M., and Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25 2 (2005) 181-200
98. Bruix J., Castells A., Bosch J., Feu F., Fuster J., Garcia-Pagan J.C., et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. Gastroenterology 111 4 (1996) 1018-1022
99. Ishizawa T., Hasegawa K., Aoki T., Takahashi M., Inoue Y., Sano K., et al. Neither multiple tumors nor portal hypertension are operative contraindications for hepatocellular carcinoma. Gastroenterology 14 6 (2008) 872-880
100. Livraghi T., Meloni F., Di Stasi M., Rolle E., Solbiati L., Tinelli C., et al. Sustained complete response and complications rate after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis. Is resection still the treatment of choice?. Hepatology 47 1 (2008) 82-89
101. Poon R.T., Fan S.T., Lo C.M., Liu C.L., and Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: Implications for a strategy of salvage transplantation. Ann Surg 235 3 (2002) 373-382
102. Ikai I., Arii S., Kojiro M., Ichida T., Makuuchi M., Matsuyama Y., et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 101 4 (2004) 796-802
103. Imamura H., Matsuyama Y., Tanaka E., Ohkubo T., Hasegawa K., Miyagawa S., et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38 2 (2003) 200-207
104. Ng I.O., Guan X.Y., Poon R.T., Fan S.T., and Lee J.M. Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol 199 3 (2003) 345-353
105. Llovet J.M., Fuster J., and Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 30 6 (1999) 1434-1440
106. Sala M., Fuster J., Llovet J.M., Navasa M., Sole M., Varela M., et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: An indication for salvage liver transplantation. Liver Transpl 10 10 (2004) 1294-1300
107. Wu C.C., Ho Y.Z., Ho W.L., Wu T.C., Liu T.J., and P'Eng F K. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: A reappraisal. Br J Surg 82 1 (1995) 122-126
108. Yamasaki S., Hasegawa H., Kinoshita H., Furukawa M., Imaoka S., Takasaki K., et al. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 87 2 (1996) 206-211
109. Lau W.Y., Leung T.W., Ho S.K., Chan M., Machin D., Lau J., et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial. Lancet 353 9155 (1999) 797-801
110. Lai E.C., Lo C.M., Fan S.T., Liu C.L., and Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: A randomized controlled trial. Arch Surg 133 2 (1998) 183-188
111. Takayama T., Sekine T., Makuuchi M., Yamasaki S., Kosuge T., Yamamoto J., et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 356 9232 (2000) 802-807
112. Iizuka N., Oka M., Yamada-Okabe H., Nishida M., Maeda Y., Mori N., et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 361 (2003) 923-929
113. Ng I.O., Guan X.Y., Poon R.T., Fan S.T., and Lee J.M. Determination of the molecular relationship between multiple tumor nodules in hepatocellular carcinoma differenciates multicentric origin from intrahepatic metastasis. J Pathol 199 3 (2003) 345-353
114. Chen Y.J., Yeh S.H., Chen J.T., Wu C.C., Hsu M.T., Tsai S.F., et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 119 (2000) 431-440
115. Finkelstein S.D., Marsh W., Demetris A.J., Swalsky P.A., Sasatomi E., Bonham A., et al. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology 37 (2003) 871-879
116. Muto Y., Moriwaki H., Ninomiya M., Adachi S., Saito A., Takasaki K.T., et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med. 334 24 (1996) 1561-1567
117. Ikeda K., Arase Y., Saitoh S., Kobayashi M., Suzuki Y., Suzuki F., et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32 2 (2000) 228-232
118. Mazzaferro V., Romito R., Schiavo M., Mariani L., Camerini T., Bhoori S., et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44 6 (2006) 1543-1554
119. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 11 (1996) 693-699
120. Jonas S., Bechstein W.O., Steinmuller T., Herrmann M., Radke C., Berg T., et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33 5 (2001) 1080-1086
121. Bismuth H., Majno P.E., and Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 19 3 (1999) 311-322
122. Llovet J.M., Bruix J., Fuster J., Castells A., Garcia-Valdecasas J.C., Grande L., et al. Liver transplantation for small hepatocellular carcinoma: The tumor-node-metastasis classification does not have prognostic power. Hepatology 27 6 (1998) 1572-1577
123. Documento de consenso de la Sociedad Española de Trasplante Hepático. Acceso al trasplante hepático, indicaciones controvertidas, priorización de la lista de espera e indicadores de calidad. Gastroenterol Hepatol 31 2 (2008) 82-91
124. Trotter J.F., Wachs M., Everson G.T., and Kam I. Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 346 14 (2002) 1074-1082
125. Todo S., and Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: Experience in Japan. Ann Surg 240 3 (2004) 451-459
126. Sarasin F.P., Majno P.E., Llovet J.M., Bruix J., Mentha G., and Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology 33 5 (2001) 1073-1079
127. Rimola A., Llovet J.M., Navasa M., Bruix J., Londono M.C., Fuster J., et al. Applicability of adult-to-adult living donor liver transplantation. J Hepatol 43 1 (2005) 104-109
128. Terrault N.A., Shiffman M.L., Lok A.S., Saab S., Tong L., Brown Jr. R.S., et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 13 1 (2007) 122-129
129. Ghobrial R.M., Freise C.E., Trotter J.F., Tong L., Ojo A.O., Fair J.H., et al. Donor morbidity after living donation for liver transplantation. Gastroenterology 135 2 (2008) 468-476
130. Garcia-Retortillo M., Forns X., Llovet J.M., Navasa M., Feliu A., Massaguer A., et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 40 3 (2004) 699-707
131. Schmeding M., Neumann U.P., Puhl G., Bahra M., Neuhaus R., and Neuhaus P. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: A single-center study of 289 patients. Liver Transpl 13 5 (2007) 687-692
132. Yao F.Y., Bass N.M., Ascher N.L., and Roberts J.P. Liver transplantation for hepatocellular carcinoma: Lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy. Liver Transpl 10 5 (2004) 621-630
133. Mazzaferro V., Battiston C., Perrone S., Pulvirenti A., Regalia E., Romito R., et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: A prospective study. Ann Surg 240 5 (2004) 900-909
134. Lu D.S., Yu N.C., Raman S.S., Limanond P., Lassman C., Murray K., et al. Radiofrequency ablation of hepatocellular carcinoma: Treatment success as defined by histologic examination of the explanted liver. Radiology 234 3 (2005) 954-960
135. Majno P.E., Adam R., Bismuth H., Castaing D., Ariche A., Krissat J., et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 226 6 (1997) 688-701
136. Graziadei I.W., Sandmueller H., Waldenberger P., Koenigsrainer A., Nachbaur K., Jaschke W., et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9 6 (2003) 557-563
137. Llovet J.M., Mas X., Aponte J.J., Fuster J., Navasa M., Christensen E., et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 50 1 (2002) 123-128
138. Yao F.Y., Ferrell L., Bass N.M., Watson J.J., Bacchetti P., Venook A., et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 33 6 (2001) 1394-1403
139. Cillo U., Vitale A., Bassanello M., Boccagni P., Brolese A., Zanus G., et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 239 2 (2004) 150-159
140. Herrero J.I., Sangro B., Pardo F., Quiroga J., Inarrairaegui M., Rotellar F., et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl 14 3 (2008) 272-278
141. Onaca N., Davis G.L., Goldstein R.M., Jennings L.W., and Klintmalm G.B. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: A report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 13 3 (2007) 391-399
142. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: A 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246(3):502-9; discussion 9-11.
143. Decaens T., Roudot-Thoraval F., Hadni-Bresson S., Meyer C., Gugenheim J., Durand F., et al. Impact of UCSF criteria according to pre and post-OLT tumor features: Analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 12 12 (2006) 1761-1769
144. Jatoi M., Puhl S., Thyagarajan V., Pelletier S., Magee J., Jeffery P., et al. Liver transplantation for hepatocellular carcinoma: Validation of the Milan Criteria using the UNOS database. Hepatology 44 4 (2006) 407A
145. Volk M.L., Vijan S., and Marrero J.A. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 8 4 (2008) 839-846
146. Otto G., Herber S., Heise M., Lohse A.W., Monch C., Bittinger F., et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 12 8 (2006) 1260-1267
147. Yao F.Y., Kerlan Jr. R.K., Hirose R., Davern III T.J., Bass N.M., Feng S., et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: An intention-to-treat analysis. Hepatology 48 3 (2008) 819-827
148. Kasahara M., Kaihara S., Oike F., Ito T., Fujimoto Y., Ogura Y., et al. Living-donor liver transplantation with monosegments. Transplantation 76 4 (2003) 694-696
149. Gondolesi G.E., Roayaie S., Munoz L., Kim-Schluger L., Schiano T., Fishbein T.M., et al. Adult living donor liver transplantation for
150. Lee S.G., Hwang S., Moon D.B., Ahn C.S., Kim K.H., Sung K.B., et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 14 7 (2008) 935-945
151. Ito T., Takada Y., Ueda M., Haga H., Maetani Y., Oike F., et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 13 12 (2007) 1637-1644
152. Sugawara Y., Tamura S., and Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 25 4 (2007) 310-312
153. Jonas S., Mittler J., Pascher A., Schumacher G., Theruvath T., Benckert C., et al. Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center. Liver Transpl 13 6 (2007) 896-903
154. Barr M.L., Belghiti J., Villamil F.G., Pomfret E.A., Sutherland D.S., Gruessner R.W., et al. A report of the Vancouver Forum on the care of the live organ donor: Lung, liver, pancreas, and intestine data and medical guidelines. Transplantation 81 10 (2006) 1373-1385
155. Sala M., Llovet J.M., Vilana R., Bianchi L., Sole M., Ayuso C., et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40 6 (2004) 1352-1360
156. Beaugrand M., N'Kontchou G., Seror O., Ganne N., and Trinchet J.C. Local/regional and systemic treatments of hepatocellular carcinoma. Semin Liver Dis 25 2 (2005) 201-211
157. Livraghi T., Giorgio A., Marin G., Salmi A., de Sio I., Bolondi L., et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection. Radiology 197 1 (1995) 101-108
158. Castellano L., Calandra M., Del Vecchio Blanco C., and de Sio I. Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: Analysis of 71 patients. J Hepatol 27 5 (1997) 862-870
159. Lencioni R., Cioni D., Crocetti L., Franchini C., Pina C.D., Lera J., et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: Long-term results of percutaneous image-guided radiofrequency ablation. Radiology 234 3 (2005) 961-967
160. Livraghi T., Solbiati L., Meloni M.F., Gazelle G.S., Halpern E.F., and Goldberg S.N. Treatment of focal liver tumors with percutaneous radio-frequency ablation: Complications encountered in a multicenter study. Radiology 226 2 (2003) 441-451
161. Tateishi R., Shiina S., Teratani T., Obi S., Sato S., Koike Y., et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1,000 cases. Cancer 103 6 (2005) 1201-1209
162. Livraghi T., Goldberg S.N., Lazzaroni S., Meloni F., Solbiati L., and Gazelle G.S. Small hepatocellular carcinoma: Treatment with radio-frequency ablation versus ethanol injection. Radiology 210 3 (1999) 655-661
163. Lencioni R.A., Allgaier H.P., Cioni D., Olschewski M., Deibert P., Crocetti L., et al. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228 1 (2003) 235-240
164. Lin S.M., Lin C.J., Lin C.C., Hsu C.W., and Chen Y.C. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or=4 cm. Gastroenterology. 127 6 (2004) 1714-1723
165. Lin S.M., Lin C.J., Lin C.C., Hsu C.W., and Chen Y.C. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54 8 (2005) 1151-1156
166. Shiina S., Teratani T., Obi S., Sato S., Tateishi R., Fujishima T., et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129 1 (2005) 122-130
167. Huang G.T., Lee P.H., Tsang Y.M., Lai M.Y., Yang P.M., Hu R.H., et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: A prospective study. Ann Surg 242 1 (2005) 36-42
168. Chen M.S., Li J.Q., Zheng Y., Guo R.P., Liang H.H., Zhang Y.Q., et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243 3 (2006) 321-328
169. Bruix J., Sala M., and Llovet J.M. Chemoembolization for hepatocellular carcinoma. Gastroenterology 127 5 Suppl 1 (2004) S179-S188
170. Lo C.M., Ngan H., Tso W.K., Liu C.L., Lam C.M., Poon R.T., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 5 (2002) 1164-1171
171. Llovet J.M., Real M.I., Montana X., Planas R., Coll S., Aponte J., et al. Arterial embolization or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359 9319 (2002) 1734-1739
172. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37 2 (2003) 429-442
173. Varela M., Real M.I., Burrel M., Forner A., Sala M., Brunet M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. J Hepatol 46 3 (2007) 474-481
174. Poon R.T., Tso W.K., Pang R.W., Ng K.K., Woo R., Tai K.S., et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5 9 (2007) 1100-1108
175. Malagari K., Chatzimichael K., Alexopoulou E., Kelekis A., Hall B., Dourakis S., et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: Results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 31 2 (2008) 269-280
176. Lencioni R., Crocetti L., Petruzzi P., Vignali C., Bozzi E., Della Pina C., et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: A pilot clinical study. J Hepatol 49 2 (2008) 217-222
177. Salem R., Lewandowski R.J., Atassi B., Gordon S.C., Gates V.L., Barakat O., et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): Safety, tumor response, and survival. J Vasc Interv Radiol 16 12 (2005) 1627-1639
178. Sangro B., Bilbao J.I., Boan J., Martinez-Cuesta A., Benito A., Rodriguez J., et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 66 3 (2006) 792-800
179. Kulik L.M., Carr B.I., Mulcahy M.F., Lewandowski R.J., Atassi B., Ryu R.K., et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47 1 (2008) 71-81
180. Yeo W., Mok T.S., Zee B., Leung T.W., Lai P.B., Lau W.Y., et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97 20 (2005) 1532-1538
181. Gish R.G., Porta C., Lazar L., Ruff P., Feld R., Croitoru A., et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 25 21 (2007) 3069-3075
182. Lopez P.M., Villanueva A., and Llovet J.M. Systematic review: Evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 23 11 (2006) 1535-1547
183. Barbare J.C., Bouche O., Bonnetain F., Raoul J.L., Rougier P., Abergel A., et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 23 19 (2005) 4338-4346
184. CLIP Group (Cancer of the Liver Italian Programme). Tamoxifen in treatment of hepatocellular carcinoma: A randomised controlled trial. Lancet 352 9121 (1998) 17-20
185. Castells A., Bruix J., Bru C., Ayuso C., Roca M., Boix L., et al. Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients. Gastroenterology 109 3 (1995) 917-922
186. Liu C.L., Fan S.T., Ng I.O., Lo C.M., Poon R.T., and Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: A prospective randomized study. Am J Gastroenterol 95 1 (2000) 218-222
187. Villa E, Ferretti I, Grottola A, Buttafoco P, Buono MG, Giannini F, et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. 2001;84(7):881-5.
188. Yuen M.F., Poon R.T., Lai C.L., Fan S.T., Lo C.M., Wong K.W., et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 36 3 (2002) 687-691
189. Allgaier H.P., Becker G., Olschewski M., et al. Octreotide treatment in patients with advanced hepatocellular carcinoma: First results of the randomized placebo-controlled double-blind Hector trial. Hepatology 38 (2003) 760A
190. Grimaldi C., Bleiberg H., Gay F., Messner M., Rougier P., Kok T.C., et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: Results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 16 2 (1998) 411-417
191. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology 40 6 (2004) 1361-1369
192. Beaugrand M., Sala M., Degos F., Sherman M., Bolondi L., Evans T., et al. Treatment of advanced hepatocellular carcinoma by seocalcitol (a vit D analogue): an International randomized double-blind placebo-controlled study in 747 patients. J Hepatol 42 (2003) 17A
193. Llovet J.M., and Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48 4 (2008) 1312-1327
194. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R.A., et al. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5 10 (2006) 835-844
195. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 19 (2004) 7099-7109
196. Abou-Alfa G.K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 26 (2006) 4293-4300
197. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 4 (2008) 378-390
198. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double blind, placebo-controlled trial. Lancet Oncol 10 (2009) 25-34
199. Abou-Alfa G, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol. 2008;26(May 20 Suppl):Abstract 4518.
200. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1673-1684
201. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 2 (2005) 123-132
202. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
203. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 6 (2006) 567-578
204. Philip P.A., Mahoney M.R., Allmer C., Thomas J., Pitot H.C., Kim G., et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23 27 (2005) 6657-6663
205. Zhu A., Sahani D., di Tomaso E., Duda V., Sindhwani V., Yoon S.S., et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 25 20 Suppl (2007) 213S
206. Faivre S., Raymond E., Douillard J., Boucher E., Lim H., Kim J., et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). Journal of Clinical Oncology 25 June 20 Suppl (2007) 3546S
207. Thomas M., Chadha R., Iwasaki M., Glover K., and Abbruzzese J. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 25 June 20 Suppl (2007) 4567S
208. Siegel A.B., Cohen E.I., Ocean A., Lehrer D., Goldenberg A., Knox J.J., et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26 18 (2008) 2992-2998